Influence of different treatment techniques on radiation dose to the LAD coronary artery
© Nieder et al; licensee BioMed Central Ltd. 2007
Received: 28 March 2007
Accepted: 05 June 2007
Published: 05 June 2007
The purpose of this proof-of-principle study was to test the ability of an intensity-modulated radiotherapy (IMRT) technique to reduce the radiation dose to the heart plus the left ventricle and a coronary artery. Radiation-induced heart disease might be a serious complication in long-term cancer survivors.
Planning CT scans from 6 female patients were available. They were part of a previous study of mediastinal IMRT for target volumes used in lymphoma treatment that included 8 patients and represent all cases where the left anterior descending coronary artery (LAD) could be contoured. We compared 6 MV AP/PA opposed fields to a 3D conformal 4-field technique and an optimised 7-field step-and-shoot IMRT technique and evaluated DVH's for several structures. The planning system was BrainSCAN 5.21 (BrainLAB, Heimstetten, Germany).
IMRT maintained target volume coverage but resulted in better dose reduction to the heart, left ventricle and LAD than the other techniques. Selective dose reduction could be accomplished, although not to the degree initially attempted. The median LAD dose was approximately 50% lower with IMRT. In 5 out of 6 patients, IMRT was the best technique with regard to heart sparing.
IMRT techniques are able to reduce the radiation dose to the heart. In addition to dose reduction to whole heart, individualised dose distributions can be created, which spare, e.g., one ventricle plus one of the coronary arteries. Certain patients with well-defined vessel pathology might profit from an approach of general heart sparing with further selective dose reduction, accounting for the individual aspects of pre-existing damage.
Intensity-modulated radiation therapy (IMRT) can be used to reduce the dose to critical organs such as the heart in mediastinal radiotherapy [1–6]. This might impact on long-term side effects especially in highly curable diseases, e.g., in patients with Hodgkin's and non-Hodgkin's lymphoma [7–10]. The current study in female patients with target volumes typical for lymphoma treatment examines the ability of a previously developed IMRT technique  to spare not only the heart as a complete organ and its chambers, for example the left ventricle, but also another well-defined region within the heart, such as, a coronary artery. As recently suggested, arteries appear to be particularly vulnerable to the effects of ionising radiation . Radiation of the endothelium might cause early functional alterations such as pro-inflammatory responses and other changes, which are slowly progressive and might interact fatally with atherosclerotic lesions. An IMRT plan optimisation that takes the localisation of a critical vessel into account in individuals with known, localised coronary artery stenosis might allow for selective dose reduction. The present study evaluates the feasibility of an already heart-sparing IMRT technique to create such an individualised dose distribution.
Materials and methods
We used the original data set of 8 female patients that formed the basis for development of our heart-sparing IMRT technique to identify the most suitable coronary artery for this study, i.e. the artery that could be reliably contoured in as many patients as possible. Females were chosen because of the challenge to obtain low breast doses in addition to heart sparing. Our attempt to reliably identify one of the coronary arteries was successful in 6 of the 8 patients. The left anterior descending artery (LAD) could be contoured with the help of a radiologist and was therefore further explored for the purpose of this study. These 6 patients were older than the others and some of them had slight vessel calcifications, which facilitated delination.
As in the original 8 patients, the coplanar single-isocenter 7-field step-and-shoot IMRT technique developed by our group (gantry angles of 0, 51, 102, 153, 204, 255, and 306°) was compared with AP/PA opposed fields and a coplanar single-isocenter 4-field technique (beam angles 0, 180, 90, and 270°). A Siemens Mevatron KD-2 linear accelerator with a 58 leaf multi-leaf collimator and leaf width of 1 cm (6 MV photons) was used. The 7 IMRT fields consisted of 13–18 sub-segments each (median 15). The gantry angles remained unchanged for all 6 cases, i.e. no individual optimization was attempted. A dose of 2 Gy per fraction was chosen for a total dose of 30 Gy, reflecting current concepts in many types of lymphoma. These doses were prescribed to the isocenter. The PTV was to be surrounded by the 95% isodose line. In IMRT, 100% of the PTV was to receive 95% of the prescribed dose. The constraints for organs at risk in IMRT were chosen as follows: absolute maximum dose to the left ventricle 50% of the prescription dose (i.e. 1 Gy), dose to 25% of the volume 25% (0.5 Gy), dose to 50% of the volume 25% (0.5 Gy), dose to 75% of the volume 20% (0.4 Gy). The heart should receive an absolute maximum dose of 75% and not more than 20% to 70% of the volume, 40% to 40% of the volume, and 60% to 20% of the volume. The planning system used for all techniques and scenarios was BrainSCAN 5.21 (BrainLAB, Heimstetten, Germany), which uses a pencil beam algorithm and heterogeneity corrections. BrainSCAN offers the option of adjusting the priority of each organ at risk relative to the others by specifying organ at risk guardian values. We assigned equally high priority to the heart, left ventricle and LAD (guardian 100%), because patients with coronary artery disease will often have myocardial damage in addition. The calculation grid size was 4 mm.
We used the Kruskal-Wallis-test for global statistic evaluation of differences in PTV and organ at risk DVH's, followed by post hoc analysis with the Mann-Whitney test (all performed with the SPSS software). A p-value < 0.05 was considered statistically significant.
The two patients that could not be included in the present LAD study were relatively young and had a. the smallest PTV and heart from the original group of 8 patients and b. intermediate values for these two parameters, respectively. No other special anatomic features distinguished the non-eligible two cases from the eligible 6 cases.
Dose to the heart and left ventricle
The results of DVH analysis remained essentially unchanged in the study group of 6 patients compared to the original group. The small target volume excluded most of the heart. Therefore, no difference between the 3 techniques could be observed . For both other target volumes, the maximum doses were comparable. Nevertheless, IMRT resulted in better dose reduction to the heart and left ventricle than both other techniques. Better heart sparing was achieved when looking at the median dose, the volume receiving 30 Gy, i.e. 100% of the prescribed dose, and all dose levels down to the 15% isodose. The heart volume receiving 10% or less of the prescribed dose was similar for all techniques. Compared to IMRT with dose constraints only to heart and left ventricle, addition of LAD sparing had no consistent impact on heart DVH's, while high-dose areas in the left ventricle tended to be slightly reduced in 5 out of 6 patients. As discussed in the next paragraph, the main problem of adding the LAD as organ at risk was to maintain target volume coverage.
Dose to the LAD coronary artery
Median doses to the left anterior descending coronary artery (LAD) in [Gy] for 3 differently sized target volumes
Maximum dose (range)*
Median dose (range)
Median volume receiving 100%
Median volume receiving 25%*
28.5 Gy (27.3–29.4)
23.4 Gy (18.3–27.0)
29.7 Gy (28.5–30.0)
21.3 Gy (13.2–26.1)
28.5 Gy (21.3–29.7)
11.1 Gy (8.7–14.1)
30.6 Gy (30.0–31.2)
30.0 Gy (26.4–30.0)
30.6 Gy (30.0–30.9)
29.0 Gy (19.2–30.3)
26.9 Gy (23.7–30.0)
15.9 Gy (10.8–29.4)
31.5 Gy (29.7–31.8)
30.5 Gy (30.2–30.6)
31.2 Gy (30.6–31.8)
28.5 Gy (21.9–29.4)
29.1 Gy (27.3–31.2)
15.9 Gy (15.0–21.9)
Results for each of the 6 patients
Magnitude of IMRT advantage in LAD sparing for both intermediate and large target volume scenarios
Would a decision for IMRT have been the preferred option also with regard to heart and left ventricle sparing?
IMRT outperformed the other techniques to just below the 25% isodose
Yes, IMRT was optimal
IMRT outperformed the other techniques to just below the 25% isodose
Yes, IMRT was optimal
IMRT outperformed the other techniques to just below the 25% isodose
Yes, IMRT was optimal
IMRT outperformed the other techniques down to the 25% isodose
Yes, IMRT was optimal
IMRT outperformed the other techniques down to the 50% isodose
IMRT and 4-field were very similar regarding total heart, but IMRT was slightly better regarding median and mean left ventricle dose (maximum doses were similar, as were ≤25% isodose levels)
IMRT and 4-field very similar, both outperformed AP/PA down to the 50% isodose
No, 4-field was best (lowest median heart dose and volume receiving 2 Gy, no disadvantage regarding maximum dose and the various low- dose parameters)
Dose to the other organs at risk and PTV
Compared to the results in the original group of 8 patients, the dose distributions in the other contoured organs at risk remained essentially unchanged. The same holds true for the finding of similar PTV coverage with all three techniques. Interestingly, the PTV was more sensitive than the organs at risk to introduction of strong LAD dose constraints.
The present extension of our systematic IMRT treatment planning study was performed in a very challenging patient population, i.e. females with different sizes of paraclavicular and mediastinal target volumes and presumed cardiac disease, necessitating selective sparing of vulnerable structures within the heart. The IMRT technique was previously developed and optimized with regard to beam angles and dose constraints by our group . We found during this process, that 7 equally-spaced beams resulted in satisfactory PTV coverage, dose homogeneity, and adherence to the normal tissue constraints. Other groups have also shown that 7-field IMRT can be a useful technique in this region of the body, e.g. in esophageal cancer [1, 2].
The aim of general heart sparing was best achieved with IMRT. Yet, high doses to some parts of the heart will still occur if the distance between the heart and PTV is marginal or even absent. It is certainly important whether such high-dose areas are located in regions with better or compromised perfusion. Therefore we decided to perform this proof-of-principle-study aiming at selective protection of a well-defined small substructure. With the available CT equipment, the LAD was the most suitable structure, which could be contoured in 6 patients. It should be noted that cardiac CT imaging protocols that use, e.g., a smaller slice thickness, would enable us to depict longer segments of the coronary tree and smaller branches . In addition, the vessel contours could be delinated more sharply and a higher contrast-to-noise ratio could be obtained. Therefore, our LAD contours might underestimate the true extent of the vessel. Irrespective of scanner parameters, the small branches will eventually disappear within the myocardium of the left ventricle, which is feeded by these branches and which was also considered as organ at risk. In our study, IMRT resulted in the lowest median LAD dose in all 3 scenarios and in the smallest volume of LAD receiving 100% of the prescribed dose and eventually provided the most suitable plan in 5 out of 6 patients. In IMRT with dose constraints to the heart and left ventricle only, maximum doses of 113% in the LAD occurred . In the present study, the maximum was reduced to 106%. But more importantly, the LAD volume receiving doses ≥100% was smaller and a pronounced sparing from intermediate doses could be obtained.
To our knowledge, no firm human data allow us to answer the question of which doses are most damaging to the coronary arteries, i.e. the "a lot to a little or a little to a lot" question. Intuitively, and supported by the data discussed by Schultz-Hector and Trott , one would like to reduce the whole area under the DVH as much as possible, but in addition obtain pronounced reductions in the high-dose regions, because it can not be assumed that a coronary artery reacts like a parallel organ. Whether the significant improvements in dose distribution by IMRT translate into clinical benefits, requires prospective confirmation. In addition, the individual magnitude of benefit from selective dose-reduction might depend on the extent of pre-existing damage. Optimal planning of such individualised dose distributions beyond a proof-of-principle study will require more information than that provided by standard-CT. Angiography, cardio-CT and/or magnetic resonance imaging will likely have to add data on individual patient anatomy and pre-existing damage. Another important question is how reliably such individual dose distributions can be transferred into daily routine, where breathing, swallowing, cardiac motion and set-up errors need to be taken into account. Therefore, assessment of the influence of motion artefacts and the need for definition of a safety margin around the LAD is necessary. It might be possible to use virtual volumes to protect small structures at risk, as described by Girinsky et al.  who found this strategy superior to dose constraints assigned to individual organs. However, a detailed discussion of gating, high-precision and 4-D radiotherapy methodology [13, 14], is beyond the scope of this article.
As described earlier, there is a price to pay for optimized heart sparing with IMRT compared to AP/PA: both a higher mean lung dose (of lesser concern with a total dose of only 30 Gy) and higher exposure of breast parenchyma to low radiation doses . However, both the mean lung dose, V20 and V30 is not higher with IMRT than with 3-D 4 fields, which is important for patients with non-lymphoma mediastinal malignancy, where AP/PA techniques clearly are inappropiate because the total doses required are much higher than 30 Gy. The IMRT disadvantages described in our patients were also found in the plan comparisons by Girinsky et al. . It appears therefore necessary to select very carefully the patients where heart sparing is of utmost importance and to weigh the benefits against the disadvantages. Further refinement is hoped to result from continued optimization of target volume concepts, e.g., based on positron emission tomography and early response evaluation during chemotherapy [15, 16], as toxicity risks will decrease with further reduction of the target volumes . Proton treatment of thoracic target volumes appears to reduce the dose to normal tissues significantly, compared with photon therapy, either 3D-conformal or IMRT . However, no planning studies of selective dose reduction to certain substructures of the heart have yet been performed and the issue of precise delivery of such plans to patients is not less complicated in proton radiotherapy.
The 7-field IMRT technique provided better heart sparing than traditional approaches in the majority of patients. In addition to dose reduction to the whole organ, individualised dose distributions can be created, which spare, e.g., one ventricle plus one of the coronary arteries. Certain patients with well-defined vessel pathology might profit from an approach of general heart sparing with further selective dose reduction, accounting for the individual aspects of pre-existing damage.
- Chandra A, Guerrero TM, Liu HH, Tucker SL, Liao Z, Wang X, Bonnen MD, Garg AK, Stevens CW, Chang JY, Jeter MD, Mohan R, Cox JD, Komaki R: Feasibility of using intensity-modulated radiotherapy to improve lung sparing in treatment planning for distal esophageal cancer. Radiother Oncol 2005, 77: 247-253. 10.1016/j.radonc.2005.10.017View ArticlePubMedGoogle Scholar
- Woudstra E, Heijmen BJ, Storchi PR: Automated selection of beam orientations and segmented intensity-modulated radiotherapy (IMRT) for treatment of oesophagus tumors. Radiother Oncol 2005, 77: 254-261. 10.1016/j.radonc.2005.06.028View ArticlePubMedGoogle Scholar
- Goodman KA, Toner S, Hunt M, Wu EJ, Yahalom J: Intensity-modulated radiotherapy for lymphoma involving the mediastinum. Int J Radiat Oncol Biol Phys 2005, 62: 198-206. 10.1016/j.ijrobp.2004.08.048View ArticlePubMedGoogle Scholar
- Girinsky T, Pichenot C, Beaudre A, Ghalibafian M, Lefkopoulos D: Is intensity-modulated radiotherapy better than conventional radiation treatment and three-dimensional conformal radiotherapy for mediastinal masses in patients with Hodgkin's disease, and is there a role for beam orientation optimization and dose constraints assigned to virtual volumes? Int J Radiat Oncol Biol Phys 2006, 64: 218-226. 10.1016/j.ijrobp.2005.06.004View ArticlePubMedGoogle Scholar
- Nieder C, Schill S, Kneschaurek P, Molls M: Comparison of three different mediastinal radiotherapy techniques in female patients: impact on heart sparing and dose to the breasts. Radiother Oncol 2007, 82: 301-307. 10.1016/j.radonc.2006.10.015View ArticlePubMedGoogle Scholar
- Dobler B, Lorenz F, Wertz H, Polednik M, Wolff D, Steil V, Lohr F, Wenz F: Intensity-modulated radiation therapy (IMRT) with different combinations of treatment-planning systems and linacs: issues and how to detect them. Strahlenther Onkol 2006, 182: 481-488. 10.1007/s00066-006-1544-6View ArticlePubMedGoogle Scholar
- Prosnitz RG, Chen YH, Marks LB: Cardiac toxicity following thoracic radiation. Semin Oncol 2005, 32: S71-80. 10.1053/j.seminoncol.2005.03.013View ArticlePubMedGoogle Scholar
- Eich HT, Haverkamp U, Engert A, Kocher M, Skripnitchenko R, Brillant C, Sehlen S, Duhmke E, Diehl V, Muller RP: Biophysical analysis of the acute toxicity of radiotherapy in Hodgkin's lymphoma – a comparison between extended field and involved field radiotherapy based on the data of the German Hodgkin Study Group. Int J Radiat Oncol Biol Phys 2005, 63: 860-865. 10.1016/j.ijrobp.2005.02.053View ArticlePubMedGoogle Scholar
- Hull MC, Morris CG, Pepine CJ, Mendenhall NP: Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy. JAMA 2003, 290: 2831-2837. 10.1001/jama.290.21.2831View ArticlePubMedGoogle Scholar
- Heidenreich PA, Schnittger I, Strauss HW, Vagelos RH, Lee BK, Mariscal CS, Tate DJ, Horning SJ, Hoppe RT, Hancock SL: Screening for coronary artery disease after mediastinal irradiation for Hodgkin's disease. J Clin Oncol 2007, 25: 43-49. 10.1200/JCO.2006.07.0805View ArticlePubMedGoogle Scholar
- Schultz-Hector S, Trott KR: Radiation-induced cardiovascular diseases: is the epidemiologic evidence compatible with the radiobiologic data? Int J Radiat Oncol Biol Phys 2007, 67: 10-18.View ArticlePubMedGoogle Scholar
- Becker CR, Ohnesorge BM, Schoepf UJ, Reiser MF: Current development of cardiac imaging with multidetector-row CT. Eur J Radiol 2000, 36: 97-103. 10.1016/S0720-048X(00)00272-2View ArticlePubMedGoogle Scholar
- Schwarz M, van der Geer J, van Herk M, Lebesque JV, Mijnheer BJ, Damen EM: Impact of geometrical uncertainties on 3D CRT and IMRT dose distributions for lung cancer treatment. Int J Radiat Oncol Biol Phys 2006, 65: 1260-1269. 10.1016/j.ijrobp.2006.03.035View ArticlePubMedGoogle Scholar
- Weiss E, Wijesooriya K, Dill SV, Keall PJ: Tumor and normal tissue motion in the thorax during respiration: Analysis of volumetric and positional variations using 4D CT. Int J Radiat Oncol Biol Phys 2007, 67: 296-307.View ArticlePubMedGoogle Scholar
- Grosu AL, Piert M, Weber WA, Jeremic B, Picchio M, Schratzenstaller U, Zimmermann FB, Schwaiger M, Molls M: Positron emission tomography for radiation treatment planning. Strahlenther Onkol 2005, 181: 483-499. 10.1007/s00066-005-1422-7View ArticlePubMedGoogle Scholar
- Yahalom J: Transformation in the use of radiation therapy of Hodgkin lymphoma: new concepts and indications lead to modern field design and are assisted by PET imaging and intensity modulated radiation therapy (IMRT). Eur J Haematol Suppl 2005, 66: 90-97.View ArticlePubMedGoogle Scholar
- Koh ES, Tran TH, Heydarian M, Sachs RK, Tsang RW, Brenner DJ, Pintilie M, Xu T, Chung J, Paul N, Hodgson DC: A comparison of mantle versus involved-field radiotherapy for Hodgkins lymphoma: reduction in normal tissue dose and second cancer risk. Radiat Oncol 2007, 2: 13. 10.1186/1748-717X-2-13PubMed CentralView ArticlePubMedGoogle Scholar
- Chang JY, Zhang X, Wang X, Kang Y, Riley B, Bilton S, Mohan R, Komaki R, Cox JD: Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2006, 65: 1087-1096. 10.1016/j.ijrobp.2006.01.052View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.